Diffuse sclerosing variant of papillary thyroid carcinoma-an update of its clinicopathological features and molecular biology

Critical Reviews in Oncology/Hematology

Volumn 94, Issue 1, 2015, Pages 64-73

  Pillai, Suja ^a   Gopalan, Vinod ^a   Smith, Robert A ^a   Lam, Alfred K Y ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

BRAF; Diffuse sclerosing variant; Molecular biology; Papillary carcinoma; Review; Thyroid

Indexed keywords

B RAF KINASE; CELL ADHESION MOLECULE; CYTOKERATIN 19; EPITHELIAL MEMBRANE ANTIGEN; GALECTIN 3; PROTEIN P53; PROTEIN P63; PROTEIN PATCHED; PROTEIN RET; RADIOACTIVE IODINE; THYROGLOBULIN; THYROID TRANSCRIPTION FACTOR 1; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; ONCOPROTEIN; PATCHED RECEPTORS;

AGE DISTRIBUTION; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CARCINOGENESIS; CLINICAL FEATURE; CLINICAL PROTOCOL; DIFFUSE SCLEROSING VARIANT OF PAPILLARY THYROID CARCINOMA; DISEASE ASSOCIATION; DISTANT METASTASIS; ECHOGRAPHY; FIBROSIS; FINE NEEDLE ASPIRATION BIOPSY; GENE MUTATION; GENE REARRANGEMENT; GENETIC ANALYSIS; HASHIMOTO DISEASE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOCYTIC THYROIDITIS; MOLECULAR BIOLOGY; POLYMERASE CHAIN REACTION; PREOPERATIVE EVALUATION; PREVALENCE; PROTEIN EXPRESSION; PSAMMOMA BODY; RADIATION EXPOSURE; SEX DIFFERENCE; SQUAMOUS CELL METAPLASIA; THYROID CARCINOMA; THYROID SURGERY; TUMOR INVASION; CARCINOMA; DISEASE MANAGEMENT; GENE EXPRESSION REGULATION; GENETICS; META ANALYSIS; METASTASIS; MUTATION; PATHOLOGY; PROGNOSIS; SCLEROSIS; THYROID NEOPLASMS;

BIOMARKERS; CARCINOMA; DISEASE MANAGEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; NEOPLASM METASTASIS; ONCOGENE PROTEINS, FUSION; PREVALENCE; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; RECEPTORS, CELL SURFACE; SCLEROSIS; THYROID NEOPLASMS;

EID: 84926087577     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.12.001     Document Type: Review

References (76)

1. Lam A.K., Lo C.Y., Lam K.S. Papillary carcinoma of thyroid: a 30-yr clinicopathological review of the histological variants. Endocr Pathol 2005, 16:323-330.
2. LiVolsi V.A., Albores-Saavedra J., Asa S.L. Papillary carcinoma. World Health Organization Classification of Tumours: Pathology and Genetics 2004, 57-66. Tumours of Endocrine Organs International Agency for Research on Cancer, Lyon. R.A. DeLellis, R.V. Llyod, P.U. Heitz, C. Eng (Eds.).
3. Vickery A.L, Carcangiu M.L., Johannessen J.V., Sobrinho-Simoes M. Papillary carcinoma. Semin Diagn Pathol 1985, 2:90-100.
4. Carcangiu M.L., Bianchi S. Diffuse sclerosing variant of papillary thyroid carcinoma. Clinicopathologic study of 15 cases. Am J Surg Pathol 1989, 13:1041-1049.
5. Wu P.S., Leslie P.J., McLaren K.M., Toft A.D. Diffuse sclerosing papillary carcinoma of thyroid: a wolf in sheep's clothing. Clin Endocrinol (Oxf) 1989, 31:535-540.
6. Soares J., Limbert E., Sobrinho-Simões M. Diffuse sclerosing variant of papillary thyroid carcinoma. A clinicopathologic study of 10 cases. Pathol Res Pract 1989, 185:200-206.
7. Fujimoto Y., Obara T., Ito Y., Kodama T., Aiba M., Yamaguchi K. Diffuse sclerosing variant of papillary carcinoma of the thyroid: clinical importance, surgical treatment and follow-up study. Cancer 1990, 66:2306-2312.
8. Mizukami Y., Nonomura A., Michigishi T., Hashimoto T., Noguchi M., Nakamura S., et al. Diffuse sclerosing variant of papillary carcinoma of the thyroid. Report of three cases. Acta Pathol Jpn 1990, 40:676-682.
9. Hayashi Y., Sasao T., Takeichi N., Kuma K., Katayama S. Diffuse sclerosing variant of papillary carcinoma of the thyroid. A histopathological study of four cases. Acta Pathol Jpn 1990, 40:193-198.
10. Gómez-Morales M., Alvaro T., Muñoz M., Garcia del Moral R., Aguilar D., Caballero T., et al. Diffuse sclerosing papillary carcinoma of the thyroid gland: immunohistochemical analysis of the local host immune response. Histopathology 1991, 184:27-33.
11. Macák J., Michal M. Diffuse sclerosing variant of papillary thyroid carcinoma. Cesk Patol 1993, 29:6-8.
12. Moreno Egea A., Rodriguez Gonzalez J.M., Sola Perez J., Soria T., Parrilla Paricio P. Clinicopathological study of the diffuse sclerosing variety of papillary cancer of the thyroid. Presentation of 4 new cases and review of the literature. Eur J Surg Oncol 1994, 20:7-11.
13. Albareda M., Puig-Domingo M., Wengrowicz S., Soldevila J., Matias-Guiu X., Caballero A., et al. Clinical forms of presentation and evolution of diffuse sclerosing variant of papillary carcinoma and insular variant of follicular carcinoma of the thyroid. Thyroid 1998, 8:385-391.
14. Chow S.M., Chan J.K., Law S.C., Tang D.L., Ho C.M., Cheung W.Y., et al. Diffuse sclerosing variant of papillary thyroid carcinoma-clinical features and outcome. Eur J Surg Oncol 2003, 29:446-449.
15. Chan J.K., Tsui M.S., Tse C.H. Diffuse sclerosing variant of papillary carcinoma of the thyroid: a histological and immunohistochemical study of three cases. Histopathology 1987, 11:191-201.
16. Hirokawa M., Kuma S., Miyauchi A., Qian Z.R., Nakasono M., Sano T., et al. Morules in cribriform-morular variant of papillary thyroid carcinoma. Immunohistochemical characteristics and distinction from squamous metaplasia. Acta Pathol, Microbiol Immunol Scand 2004, 112:275-282.
17. Thompson L.D., Wieneke J.A., Heffess C.S. Diffuse sclerosing variant of papillary thyroid carcinoma: a clinicopathologic and immunophenotypic analysis of 22 cases. Endocr Pathol 2005, 16:331-348.
18. Lam A.K., Lo C.Y. Diffuse sclerosing variant of papillary carcinoma of the thyroid: a 35-year comparative study at a single institution. Ann Surg Oncol 2006, 13:176-181.
19. Falvo L., Giacomelli L., D'Andrea V., Marzullo A., Guerriero G., de Antoni E. Prognostic importance of sclerosing variant in papillary thyroid carcinoma. Am Surg 2006, 72:438-444.
20. Odashiro D.N., Nguyen G.K. Diffuse sclerosing variant papillary carcinoma of the thyroid: report of four cases with fine-needle aspirations. Diagn Cytopathol 2006, 34:247-249.
21. Lee J.H., Lee E.S., Kim Y.S., Won N.H., Chae Y.S. BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology 2006, 38:201-204.
22. Sheu S.Y., Schwertheim S., Worm K., Grabellus F. Schmid KW Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements. Mod Pathol 2007, 20:779-787.
23. Fukushima M., Ito Y., Hirokawa M., Akasu H., Shimizu K., Miyauchi A. Clinicopathologic characteristics and prognosis of diffuse sclerosing variant of papillary thyroid carcinoma in Japan: an 18-year experience at a single institution. World J Surg 2009, 33:958-962.
24. Takagi N., Hirokawa M., Nobuoka Y., Higuchi M., Kuma S., Miyauchi A. Diffuse sclerosing variant of papillary thyroid carcinoma: a study of fine needle aspiration cytology in 20 patients. Cytopathology 2014, 25:199-204.
25. Koo J.S., Shin E., Hong S.W. Immunohistochemical characteristics of diffuse sclerosing variant of papillary carcinoma: comparison with conventional papillary carcinoma. Acta Pathol, Microbiol Immunol Scand 2010, 118:744-752.
26. Koo J.S., Hong S., Park C.S. Diffuse sclerosing variant is a major subtype of papillary thyroid carcinoma in the young. Thyroid 2009, 19:1225-1231.
27. Kwak J.Y., Kim E.K., Hong S.W., Oh K.K., Kim M.J., Park C.S., et al. Diffuse sclerosing variant of papillary carcinoma of the thyroid: ultrasound features with histopathological correlation. Clin Radiol 2007, 62:382-386.
28. Zhang Y., Xia D., Lin P., Gao L., Li G., Zhang W. Sonographic findings of the diffuse sclerosing variant of papillary carcinoma of the thyroid. J Ultrasound Med 2010, 29:1223-1226.
29. Kazaure H.S., Roman S.A., Sosa J.A. Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 Patients. Ann Surg Oncol 2012, 19:1874-1880.
30. Regalbuto C., Malandrino P., Tumminia A., Le Moli R., Vigneri R., Pezzino V. A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases. Thyroid 2011, 21:383-389.
31. Yun M.B., Sundar P.S., Lan P.Y., Ying S.X., Hua Z. Ultrasonographic features of diffuse sclerosing variant of papillary thyroid carcinoma. J Med Ultrasound 2011, 19:41-46.
32. Chang W.C., Chen J.Y., Lee C.H., Yang A.H. Expression of decoy receptor 3 in diffuse sclerosing variant of papillary thyroid carcinoma: correlation with m2 macrophage differentiation and lymphatic invasion. Thyroid 2013, 23:720-726.
33. Sywak M., Pasieka J.L., Ogilvie T. A review of thyroid cancer with intermediate differentiation. J Surg Oncol 2004, 86:44-54.
34. Carling T., Ocal I.T., Udelsman R. Special variants of differentiated thyroid cancer: does it alter the extent of surgery versus well-differentiated thyroid cancer. World J Surg 2007, 31:916-923.
35. Fridman M.V., Savva N.N., Krasko O.V., Zborovskaya A.A., Mankovskaya S.V., Kurt Werner S., et al. Clinical and pathologic features of sporadic papillary thyroid carcinoma registered in the years 2005 to 2008 in children and adolescents of Belarus. Thyroid 2012, 22:1016-1024.
36. Nikiforov Y., Gnepp D.R. Pediatric thyroid cancer after the Chernobyl disaster. Pathomorphologic study of 84 cases (1991-1992) from the Republic of Belarus. Cancer 1994, 74:748-766.
37. Kuo C.S., Tang K.T., Lin J.D., Yang A.H., Lee C.H., Lin H.D. Diffuse sclerosing variant of papillary thyroid carcinoma with multiple metastases and elevated serum carcinoembryonic antigen level. Thyroid 2012, 22:1187-1190.
38. Lam K.Y., Lo C.Y., Chan K.W., Wan K.Y. Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann Surg 2000, 231:329-338.
39. Lee J.H., Kim Y., Choi J.W., Kim Y.S. The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis: a meta-analysis. Eur J Endocrinol 2013, 168:343-349.
40. Smith R.A., Salajegheh A., Weinstein S., Nassiri M., Lam A.K. Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. Hum Pathol 2011, 42:500-506.
41. Chen C.C., Chen W.C., Peng S.L., Huang S.M. Diffuse sclerosing variant of thyroid papillary carcinoma: diagnostic challenges occur with Hashimoto's thyroiditis. J Formos Med Assoc 2013, 112:358-362.
42. Furlan J.C., Bedard Y.C., Rosen I.B. Role of fine-needle aspiration biopsy and frozen section in the management of papillary thyroid carcinoma subtypes. World J Surg 2004, 28:880-885.
43. Gupta S., Sodhani P., Jain S., Kumar N. Morphologic spectrum of papillary carcinoma of the thyroid: role of cytology in identifying the variants. Acta Cytol 2004, 48:795-800.
44. Kwak J.Y., Kim E.K., Hong S.W., Kim M.J., Moon H.J., Park C.S. Value of specimen radiographs in diagnosing multifocality of thyroid cancer. Br J Surg 2010, 97:517-524.
45. Kwak J.Y., Kim E.K., Hong S.W., Moon H.J., Kim M.J., Son E.J., et al. Diffuse sclerosing variant of papillary carcinoma of the thyroid gland: specimen radiographic features with histopathological correlation. J Clin Endocrinol Metab 2009, 94:1491-1492.
46. Xu Y.H., Song H.J., Qiu Z.L., Luo Q.Y. Extensive lymph node metastases found by (18) F-FDG-PET/CT in a patient with diffuse sclerosing variant of papillary thyroid carcinoma. Hell J Nucl Med 2011, 14:188-189.
47. Imamura Y., Kasahara Y., Fukuda M. Multiple brain metastases from a diffuse sclerosing variant of papillary carcinoma of the thyroid. Endocr Pathol 2000, 11:97-108.
48. Kuo E.J., Goffredo P., Sosa J.A., Roman S.A. Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis. Thyroid 2013, 23:1305-1311.
49. Lloyd R.V., Buehler D., Khanafshar E. Papillary thyroid carcinoma variants. Head Neck Pathol 2011, 5:51-56.
50. Lam K.Y., Lui M.C., Lo C.Y. Cytokeratin expression profiles in thyroid carcinomas. Eur J Surg Oncol 2001, 27:631-635.
51. Vrabie C.D., Terzea D., Petrescu A., Waller M. The histopathology analysis of the diffuse sclerosing variant of the papillarycarcinoma of the thyroid: a distinctive and rare form. Rom J Morphol Embryol 2009, 50:743-748.
52. Kinoshita Y., Takasu K., Yuri T., Yoshizawa K., Emoto Y., Tsubura A., et al. Estrogen receptor- and progesterone receptor-positive diffuse sclerosing variant of papillary thyroid carcinoma: a case report. Case Rep Oncol 2013, 6:216-223.
53. Chang H.W., Chow V., Lam K.Y., Wei W.I., Yuen A. Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. Cancer 2002, 94:386-392.
54. Chow V., Yuen A.P.W., Lam K.Y., Tsao G.S.W., Ho W.K., Wei W.I. A comparative study of the clinicopathological significance of E-cadherin and catenins (α,β,γ) expression in the surgical management of oral tongue carcinoma. J Cancer Res Clin Oncol 2001, 127:59-63.
55. Si H.X., Tsao S.W., Lam K.Y., Srivastava G., Liu Y., Wong Y.C., et al. E-cadherin expression is commonly downregulated by CpG island hypermethylation in esophageal carcinoma cells. Cancer Lett 2001, 173:71-78.
56. Rocha A.S., Soares P., Seruca R., Máximo V., Matias-Guiu X., Cameselle-Teijeiro J., Sobrinho-Simões M. Abnormalities of the E-cadherin/catenin adhesion complex in classical papillary thyroid carcinoma and in its diffuse sclerosing variant. J Pathol 2001, 194:358-366.
57. Lam K.Y., Law S., Lo T., Tung H.M., Wong J. The clinicopathological significance of p21 and p53 expression in esophageal squamous cell carcinoma: an analysis of 153 patients. Am J Gastroenterol 1999, 94:2060-2068.
58. Boslooper K., Lam A.K.Y., Gao J., Weinstein S., Johnson N. The clinicopathological roles of alpha-B-crystallin and p53 expression in patients with head and neck squamous cell carcinoma. Pathology 2008, 40:500-504.
59. Weekes J., Ho Y.H., Sebesan S., Ong K., Lam A.K. Irinotecan and colorectal cancer: the role of p53, VEGF-C and alpha-B-crystallin expression. Int J Colorectal Dis 2010, 25:907.
60. Santoro M., Thomas G.A., Vecchio G., Williams G.H., Fusco A., Chiappetta G., et al. Gene rearrangement and Chernobyl related thyroid cancers. Br J Cancer 2000, 82:315-322.
61. Lam K.Y., Montone K.T., Nolan K.A., LiVolsi V.A. Ret oncogene activation in papillary thyroid carcinoma: prevalence and implication on the histological parameters. Hum Pathol 1998, 29:565-568.
62. Klugbauer S., Lengfelder E., Demidchik E.P., Rabes H.M. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene 1995, 11:2459-2467.
63. Nikiforov Y.E. RET/PTC rearrangement in thyroid tumors. Endocr Pathol 2002, 13:3-16.
64. Fagin J.A. Perspective: lessons learned from molecular genetic studies of thyroid cancer-insights into pathogenesis and tumor-specific therapeutic targets. Endocrinology 2002, 143:2025-2028.
65. Lam K.Y., Lo C.Y., Leung P.S. High prevalence of RET protooncogene activation (RET/PTC) in papillary thyroid carcinomas. Eur J Endocrinol 2002, 147:741-745.
66. Pakneshan S., Salajegheh A., Smith R.A., Lam A.K. Clinicopathological relevance of BRAF mutations in human cancer. Pathology 2013, 45:346-356.
67. Lin X., Finkelstein S.D., Zhu B., Silverman J.F. Molecular analysis of multifocal papillary thyroid carcinoma. J Mol Endocrinol 2008, 41:195-203.
68. Pratilas C.A., Taylor B.S., Ye Q., Viale A., Sander C., Solit D.B., et al. (V600E) BRAF is associated with disabled feedback inhibition of RAF-MEK signalling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A 2009, 106:4519-4524.
69. Rahman M.A., Salajegheh A., Smith R.A., Lam A.K. B-Raf mutation. A key player in molecular biology of cancer. Exp Mol Pathol 2013, 95:336-342.
70. Xing M., Alzahrani A.S., Carson K.A., Viola D., Elisei R., Bendlova B., et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. J Am Med Assoc 2013, 309:1493-1501.
71. Lim J.Y., Hong S.W., Lee Y.S., Kim B.W., Park C.S., Chang H.S., et al. Clinicopathologic implications of the BRAF (V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center. Thyroid 2013, 23:1423-1430.
72. Asioli S., Erickson L.A., Sebo T.J., Zhang J., Jin L., Thompson G.B., et al. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases. Am J Surg Pathol 2010, 34:44-52.
73. Koperek O., Kornauth C., Capper D., Berghoff A.S., Asari R., Niederle B., et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 2012, 36:844-850.
74. Frattini M., Ferrario C., Bressan P., Balestra D., De Cecco L., Mondellini P., et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004, 23:7436-7440.
75. Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003, 63:1454-1457.
76. Soares P., Trovisco V., Rocha A.S., Lima J., Castro P., Preto A., et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003, 22:4578-4580.